A Biomarker Study of ATH434 in Participants With MSA
NCT05864365 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-04-01
Summary
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
Conditions
Interventions
- DRUG
-
ATH434
ATH434 taken by mouth two times per day
Sponsors & Collaborators
-
Alterity Therapeutics
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 30 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-23
- Primary Completion
- 2025-02-26
- Completion
- 2025-02-26
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119 ·Status: RECRUITING ·Phase: PHASE1
-
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
NCT05167721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy
NCT00911365 ·Status: COMPLETED ·Phase: PHASE2
-
Effect and Safety MABs Administration m.3243A>G Mutation Carriers
NCT05962333 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
NCT01906658 ·Status: COMPLETED ·Phase: PHASE2
-
Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT01142856 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
NCT05824169 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
NCT05104476 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
NCT06765733 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
NCT04632225 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple System Atrophy Multidisciplinary Clinic
NCT03811808 ·Status: RECRUITING
-
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
NCT06421831 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT02460679 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01777646 ·Status: COMPLETED ·Phase: PHASE2
-
Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis
NCT02116634 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy
NCT06288230 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
NCT01910168 ·Status: COMPLETED
-
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
NCT05775848 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
RT001 in Amyotrophic Lateral Sclerosis
NCT04762589 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing the Fertility Status of Men With Spinal Muscular Atrophy (SMA)
NCT06194539 ·Status: RECRUITING
-
A Study of TAK-341 in Treatment of Multiple System Atrophy
NCT05526391 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren
NCT03796637 ·Status: COMPLETED ·Phase: PHASE2